Background: To evaluate the clinical and economic impact of a
specialty care management program among patients with multiple sclerosis.Methods: This retrospective cohort analysis included patients aged
≥18 years with ≥2 claims of multiple
sclerosis diagnosis and ≥1 multiple sclerosis medications from 1
January 2004 to 30 April 2008. The outcome metrics included medication adherence
and persistence, multiple sclerosis-related hospitalization, and multiple
sclerosis-related cost. Multivariate analyses were performed to adjust for
demographics and clinical characteristics.Results: Among the 3993 patients identified, 78.3%
participated in the program and 21.7% did not. Over
12 months, medication adherence and persistence improved among
participants but deteriorated among non-participants (medication possession
ratio change: +0.08 vs −0.03,
p < 0.001; persistence
change: +29.2 days vs −9.2 days,
p < 0.001). Multiple
sclerosis-related hospitalization decreased from 9.6% to
7.1% for participants, whereas it increased from 10.1%
to 12.0% for the non-participant group
(p < 0.001). Multiple
sclerosis-related medical spending (non-pharmacy) decreased among participants,
but it increased among non-participants (mean: −US$264
vs + US$1536,
p < 0.001). Total multiple
sclerosis-related cost for both groups increased over time
(+US$4471 vs +US$4087,
p < 0.001).Conclusions: This program was associated with improved medication
adherence and persistence, reduced multiple sclerosis-related hospitalization,
and decreased multiple sclerosis-related medical costs. Unfortunately, the cost
savings in the medical component did not offset the increased pharmacy
expenditures during the 12-month follow-up period.